Maelstrom Research Staging | seroMARK_VR_non_Black_Canadians_4_6_weeks_post_dose

seroMARK_VR_non_Black_Canadians_4_6_weeks_post_dose_2

Networks -

Variables -

Associated study seroMARK-VR Contingency Table

Population

seroMARK-VR - non-Black Canadians

The population is composed of children over 12 and adults who identify as non-African Canadian who reside in Ontario, Quebec, Nova Scotia and British Columbia.

Selection Criteria

Newborns

Twins

Countries

Canada

Territory

Ethnic Origin

Health Status

Exclusion criteria: Presence of symptomatic respiratory tract infection or other symptoms consistent with COVID-19 at the time of blood sampling, and known immunodeficiency, including HIV/AIDS patients with CD4 counts less than 500 per cubic mm.

Other Criteria

All ages which are eligible to receive the COVID-19 vaccine based on most updated eligibility criteria in the province.

Recruitment

Sources of recruitment

General population
Participants from existing studies

General Population

Volunteer enrolment
Selected sample

Supplementary Information

Participants will be recruited from 3 sources. * A COVID-19 seroprevalence study of Black and non-Black Canadians in COVID-19 hot spots in Ontario. These persons are enrolled through random sampling. * A random survey of person in predominantly Black neighbourhoods to identify those who were vaccinated but are not in our seroprevalence study. * Data from 8 combined cycles of the National Population Health Survey (1996-97) and the Canadian Community Health Survey (2001 through 2014).

Participants from Existing Studies

Seroprevalence of SARS-CoV-2 among African Canadians: Clinical and Epidemiological Correlates
National Population Health Survey (1996-97)
Canadian Community Health Survey (2001 through 2014)

Number of Participants

Number of Participants: 500
Number of Participants with Biological Samples: 500

More info

Data Collection Event

seroMARK-VR - non-Black Canadians - 4-6 weeks post-dose 2

Clinical data was collected including chronic medical conditions (e.g., chronic kidney disease, diabetes) and medications that might affect the immune responses to COVID-19 vaccines. The types of vaccines and dates received were recorded, as well as adverse events. A venous blood sample was collected.

More info

Collected Dataset / seroMARK_VR_non_Black_Canadians_4_6_weeks_post_dose_2

seroMARK_VR_non_Black_Canadians_4_6_weeks_post_dose_2

Population

seroMARK-VR - non-Black Canadians

Data Collection Event

seroMARK-VR - non-Black Canadians - 4-6 weeks post-dose 2

Files

Variables Classifications